Cargando…
Overcoming Barriers to Development of Novel Therapies for Cardiovascular Disease: Insights From the Oncology Drug Development Experience
Despite the fact that cardiovascular disease (CVD) is the number 1 cause of death globally, investment in drug development and new drug approvals for CVD are precipitously declining. In contrast, the trajectory of both investment in development as well as new drug approvals for oncology have been in...
Autores principales: | Khakoo, Aarif Y., Yurgin, Nicole R., Eisenberg, Paul R., Fonarow, Gregg C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488739/ https://www.ncbi.nlm.nih.gov/pubmed/31061928 http://dx.doi.org/10.1016/j.jacbts.2019.01.011 |
Ejemplares similares
-
Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012
por: Hwang, Thomas J., et al.
Publicado: (2016) -
Overcoming barriers to effective feedback: a solution-focused faculty development approach
por: McCutcheon, Samar, et al.
Publicado: (2020) -
Lights and Shadows in Immuno-Oncology Drug Development
por: Bergamino Sirvén, Milana, et al.
Publicado: (2021) -
Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions
por: Ajufo, Ezimamaka, et al.
Publicado: (2023) -
Decentralized Clinical Trials: The Future of Medical Product Development?∗
por: Van Norman, Gail A.
Publicado: (2021)